Illumina, Inc.
Financials
Valuation Metrics
Illumina, Inc.'s Market Cap is $30.02B. At end of 2025 it was $20.07B. Ranked #463 of 3,112 in US market (top 15%), #137 of 1,445 on NASDAQ (top 9%), #31 of 206 in Health Care Equipment & Services (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $30.02B | US#463/3,112 Sec#31/206 |
| Revenue | $4.39B | US#980/3,112 Sec#55/206 |
| Net Income | $853M | US#592/3,112 Sec#35/206 |
| Total Assets | $6.56B | US#1,241/3,112 Sec#55/206 |
| Net Assets | $2.68B | US#1,054/3,112 Sec#53/206 |
| Employees | 8,600 | US#648/3,112 Sec#60/206 |
| Value | ||
| P/E | 35.19x | US#1,598/3,112 Sec#65/206 |
| P/B | 11.22x | US#2,653/3,112 Sec#174/206 |
| PEG | 15.37x | US#1,290/3,112 Sec#64/206 |
| P/S | 6.84x | US#2,488/3,112 Sec#175/206 |
| EV/EBITDA | 22.35x | US#1,955/3,112 Sec#94/206 |
| FCF Yield | 3.29% | US#1,704/3,112 Sec#102/206 |
| Profitability | ||
| ROE | 31.88% | US#272/3,112 Sec#12/206 |
| ROA | 13.01% | US#275/3,112 Sec#16/206 |
| Op. Margin | 21.45% | US#823/3,112 Sec#25/206 |
| Revenue Growth | 4.80% | US#1,751/3,112 Sec#132/206 |
| Earnings Growth | 2.29% | US#1,327/3,112 Sec#67/206 |
| Financial Health | ||
| Debt Ratio | 145.10% | US#1,459/3,112 Sec#135/206 |
| Total Debt | $2.54B | US#999/3,112 Sec#48/206 |
| FCF | $989M | US#577/3,112 Sec#37/206 |
| Cash | $1.09B | US#646/3,112 Sec#34/206 |
| Current Ratio | 1.75x | US#1,435/3,112 Sec#126/206 |
| Net Debt/EBITDA | 1.03x | US#1,032/3,112 Sec#56/206 |
| Performance | ||
| 1Y Return | 109.59% | US#304/3,112 Sec#26/206 |
| 1M Return | 5.15% | US#943/3,112 Sec#75/206 |
| From 52W High | -4.15% | US#464/3,112 Sec#31/206 |
| 1Y MDD | -25.66% | US#1,078/3,112 Sec#29/206 |
| Trading | ||
| Volume | 2,237,149 shares | US#813/3,112 Sec#49/206 |
| Trading Value | $450M | US#232/3,112 Sec#15/206 |
| Per Share | ||
| EPS | $5.56 | US#586/3,112 Sec#39/206 |
| BPS | $17.80 | US#1,319/3,112 Sec#75/206 |
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.